Hims & Hers Health (NYSE:HIMS) just picked up a high-profile endorsement. JPMorgan analyst Cory Carpenter initiated coverage ...

The pharmaceutical industry has rarely seen a stock rise as spectacularly as Novo Nordisk (NVO 0.69%) did during the GLP-1 ...

Novo Nordisk’s oral semaglutide met its main goal in a late-stage trial for children with type 2 diabetes, paving the way for a U.S. launch of the Ozempic pill. Amazon is entering active GLP-1 care ...

Lilly stock falls as Foundayo trails Wegovy in early uptake. Foundayo prescriptions rise, but lag Novo’s oral Wegovy.

Three years ago, Eli Lilly ( LLY 2.40%) and Novo Nordisk ( NVO +1.87%) had about the same market value. Given how well both ...

April 23 (Reuters) - Novo Nordisk's oral GLP-1 drug significantly lowered blood sugar levels in children and adolescents with ...

Novo Nordisk said April 23 it plans to seek expanded FDA approval for its Ozempic pill in the second half of 2026, which would make the drug the first oral GLP-1 approved for children and adolescents ...

Novo Nordisk’s oral semaglutide significantly lowered blood sugar in children and adolescents with type 2 diabetes in a late-stage trial, marking the first success for an oral GLP-1 therapy in this ...

By Sriparna Roy April 24 (Reuters) - Eli Lilly's newly launched weight-loss pill had a modest second week, analysts said on ...

Hims & Hers Health (NYSE:HIMS) shares are up 9% in early trading Monday, climbing from $28.82 to $31 and change as investors ...

Novo Nordisk's oral GLP‑1 diabetes pill lowered blood sugar in children and teens with type 2 diabetes in a late-stage trial, potentially becoming the first approved oral GLP‑1 therapy for young ...

Novo Nordisk, the maker of popular weight-loss drugs Ozempic and Wegovy, is partnering with OpenAI to deploy the technology ...